Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry
  1. WHRI
  2. People
  3. Academic staff
  4. Items

Dr David Collier

Clinical Director

Centre: Clinical Research Centre, Clinical Pharmacology and Precision Medicine

Email: d.j.collier@qmul.ac.uk
Telephone: +44(0) 20 7882 5666

Profile

ORCID iD: 0000-0003-0866-4058

David is interested in recruitment and patient engagement and ran the successful “Future of Clinical Trials in the UK?” meeting in 2008 and “Everything you wanted to know about clinical trials but were too afraid to ask” for PCRN and Barts NIHR Cardiovascular BRU in 2011. Clinical Trials- Sharing Our Stories in July 2013 included trials patients, U3A members and co-ordinators, health psychology undergraduates from Florida State University, and sixth form students from a wide area under the banner of Trials Connect.

He is co-holder of an MRC programme grant examining recruitment methods for clinical trials (START) with the NIHR PCRN Research Recruitment Methods Group (ResRecMG), and is part of the NIHR Cardiovascular Biomedical Research Unit at Barts and The London.

David founded the East London spoke for the Primary Care Research Network for Greater London (PCRN-GL).

Renal Denervation with Dr Mel Lobo was a UK first in 2010 which yielded both a front page banner headline in the Daily Telegraph and National TV news on News at 6 O’clock and News at Ten for Dr Lobo and Fred Quatromini.

The first case in the world of renal sympathetic nerve denervation to bilateral renal arteries was done here as part of this study cohort.The subsequent publication in the Lancet for Dr Lobo and Professor Caulfield for Symplicity 2

Patients presented with David to the audience at both of the National Symposia on Renal Denervation – the first in October 2011 (Fred Quatromini), the second in 2012 (Sheila Milson and Anthony Henry), both at the Royal College of Physicians.

After the First UK Symposium on Renal Denervation in 2011, there was an initial meeting of the Joint British Societies to develop guidelines for renal denervation. Subsequent meetings developed a consensus statement and two of our patients, John Bold and Anthony Henry, contributed to meeting discussions and provided comments on the statement, especially with reference to the suggested patient information sheet for the procedure. 

Research

Dr David Collier is Research Fellow and Joint Clinical Director of the William Harvey Research Institute Clinical Research Centre. Now based at the Heart Centre at Barts, David ran the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) team for Professor Caulfield at Barts/London, which broke the national record for recruitment into such a trial (recruiting 1157 patients). As top academic recruiters for several studies across over a decade, this team has contributed to high-impact work such as ILLUMINATE, with 148 patients (NEJM 2007 Barter, Caulfield et al ).

ASCOT became a landmark trial and precipitated the development of joint NICE/BHS guidelines for hypertension after the publication of the Blood Pressure Lowering Arm (BPLA) in the Lancet in 2005 (prior to this time there had been separate NICE and BHS (British Hypertension Society) Guidelines on the treatment of hypertension in the UK- which had been unhelpful.

ASCOT impacted the lipid guidance from NICE on statin use in primary prevention of ischaemic heart disease and stroke- bringing routine use of statins for people at elevated absolute risk, regardless of starting levels of cholesterol.

The experience of ASCOT and local GP’s reactions to it such as “what did you do with Mrs Smith that I hadn’t done- you got her pressure down?” led David to obtain initial funds as unconditional educational grants from rival pharma companies Pfizer and Merck and to design HiLo, a health services intervention trial. Having designed the trial interventions with Dr Catherine Will (then Cambridge, now University of Sussex) and piloted them at Chrisp Street in Limehouse, the design was developed with Dr John Robson and Prof Sandra Eldridge. 

Publications

  • Simader FA, Rajkumar CA, Foley MJ et al. (2024). Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease. nameOfConference


  • Bakris GL, Saxena M, Gupta A et al. (2024). RNA Interference With Zilebesiran for Mild to Moderate Hypertension. nameOfConference


  • Collier DJ, Taylor M, Godec T et al. (2024). Personalized Antihypertensive Treatment Optimization With Smartphone‐Enabled Remote Precision Dosing of Amlodipine During the COVID‐19 Pandemic (PERSONAL‐CovidBP Trial). nameOfConference


  • Gupta A, Whiteley WN, Godec T et al. (2024). Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial. nameOfConference


  • Rajkumar CA, Foley MJ, Ahmed-Jushuf F et al. (2023). A Placebo-Controlled Trial of Percutaneous Coronary Intervention for Stable Angina. nameOfConference


  • Madurasinghe VW, Knapp P, Eldridge S et al. (publicationYear). Can we achieve better trial recruitment by presenting patient information through multimedia? Meta-analysis of ‘studies within a trial’ (SWATs). nameOfConference


    QMRO: qmroHref
  • Pairo-Castineira E, Rawlik K, Bretherick AD et al. (2023). Author Correction: GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 (Nature, (2023), 617, 7962, (764-768), 10.1038/s41586-023-06034-3). nameOfConference


  • Clohisey S, Millar J, Shankar-Hari M et al. (2023). GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19. nameOfConference


  • Schlaich MP, Bellet M, Weber MA et al. (2022). Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. nameOfConference


  • Nowbar AN, Howard JP, Shun-Shin MJ et al. (2022). Daily angina documentation versus subsequent recall: development of a symptom smartphone app. nameOfConference


    QMRO: qmroHref
  • Florescu S, Stanciu D, Zaharia M et al. (2022). Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19. nameOfConference


    QMRO: qmroHref
  • Nowbar AN, Rajkumar C, Foley M et al. (2022). A double-blind randomised placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina without antianginal medications: design and rationale of the ORBITA-2 trial.. nameOfConference


    QMRO: qmroHref
  • Taylor M, Godec T, Shiel J et al. (2022). WHOSE DOSE IS IT ANYWAY? INDIVIDUAL PATIENT DOSE-RESPONSE CURVES FROM THE REMOTE-CARE PERSONAL-COVIDBP TRIAL. nameOfConference


    QMRO: qmroHref
  • Astbury S, Reynolds CJ, Butler DK et al. (2022). HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19. nameOfConference


  • Baillie JK, Begg C, Clohisey Hendry S et al. (2022). Whole-genome sequencing reveals host factors underlying critical COVID-19. nameOfConference


  • Wolff CB, Green DW, Paton JFR et al. (2022). New understanding of circulatory blood flow and arterial blood pressure mechanisms. nameOfConference


  • Collier D, Taylor M, Godec T et al. (2022). Personalized electronic record supported optimisation when alone for patients with hypertension- pilot study for remote medical management of hypertension during the Covid-19 pandemic (personal covidBP). nameOfConference

    DOI: doi

  • Swadling L, Diniz MO, Schmidt NM et al. (2021). Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. nameOfConference


  • Madurasinghe VW, Bower P, Eldridge S et al. (2021). Can we achieve better recruitment by providing better information? Meta-analysis of ‘studies within a trial’ (SWATs) of optimised participant information sheets. nameOfConference


  • Niemi MEK, Karjalainen J, Liao RG et al. (2021). Mapping the human genetic architecture of COVID-19. nameOfConference


  • Gupta RK, Rosenheim J, Bell LC et al. (2021). Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study.. nameOfConference


  • Zenner D (2021). The Barts Health NHS Trust COVID-19 cohort: characteristics, outcomes and risk scoring of patients in East London. nameOfConference


  • Reynolds CJ, Pade C, Gibbons JM et al. (2021). Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. nameOfConference


  • Pairo-Castineira E, Clohisey S, Klaric L et al. (2021). Genetic mechanisms of critical illness in COVID-19.. nameOfConference


  • Collier DJ, Wielders P, van der Palen J et al. (publicationYear). Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease. nameOfConference


  • Martinez FJ, Lipworth BJ, Rabe KF et al. (2020). Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. nameOfConference


  • CB W, DW G, JFR P et al. (2020). A New Radically Improved Model of the Circulation With Important Clinical Implications. nameOfConference


  • Souza PR, Marques RM, Gomez EA et al. (2019). Enriched Marine Oil Supplements Increase Peripheral Blood Specialized Pro-Resolving Mediators Concentrations and Reprogram Host Immune Responses: A Randomized Double-Blind Placebo-Controlled Study.. nameOfConference


  • James WY, James WY, Collier D (2019). Is electronic diary alert a false alarm in clinical studies?. General practice and primary care


    QMRO: qmroHref
  • Lipworth BJ, Collier DJ, Feldman GJ et al. (2019). Benefits of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) in Symptomatic Patients with COPD: A Post-Hoc Analysis from a Phase III, Randomized, Placebo-Controlled Study (PINNACLE-4). B45. COPD: TREATMENT


    QMRO: qmroHref
  • Collier D, Wielders P, van der Palen J et al. (2019). Critical Error Rates with the ELLIPTA Inhaler Compared with Other Dry-Powder Inhalers in Patients with COPD: An Open-Label, Low-Intervention Clinical Study. A102. COPD: THERAPY


    QMRO: qmroHref
  • McGuire DK, Alexander JH, Johansen OE et al. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. nameOfConference


    QMRO: qmroHref
  • Rosenstock J, Perkovic V, Johansen OE et al. (2019). Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Juhasz A, Agabiti‐Rosei E et al. (2018). Efficacy and safety of azilsartan medoxomil/chlortalidone fixed‐dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial. nameOfConference


  • Lipworth BJ, Collier DJ, Gon Y et al. (2018). Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA.. nameOfConference


  • MADURASINGHE VW, Parker A, Knapp P et al. (2018). The effect of optimised patient information materials on recruitment in a lung cancer screening trial: an embedded randomised recruitment trial. nameOfConference


  • Saxena M, Shour T, Shah M et al. (2018). Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success.. nameOfConference


  • BROWN MJ (2018). Investigation of the endocrine and haemodynamic changes in resistant hypertension, and its response to spironolactone or amiloride: the PATHWAY-2 mechanisms study. nameOfConference


  • Mukhtar O, Cheriyan J, Cockcroft JR et al. (2018). A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYpertension program—AIM-HY INFORM trial. nameOfConference


    QMRO: qmroHref
  • Lipworth B, Collier DJ, Gon Y et al. (2018). Glycopyrrolate/Formoterol Fumarate Fixed-Dose Combination Delivered by Metered Dose Inhaler Improves Lung Function and Symptoms in Patients with COPD: Results from the PINNACLE-4 Study in Asia, Europe, and the USA. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • MacDonald TM, Williams B, Webb DJ et al. (2017). Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.. nameOfConference


  • Al-Lamee R, Thompson D, Dehbi H-M et al. (2018). Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. nameOfConference


  • Saxena M, Shour T, Shah M et al. (2017). [LB.03.06] ATTENUATION OF SPLANCHNIC AUTOTRANSFUSION FOLLOWING NON-INVASIVE ULTRASOUND RENAL DENERVATION. nameOfConference


  • SAXENA M, Shour T, Sobotka P et al. (2017). [PP.24.26] ANTIHYPERTENSIVE EFFECTS OF A CENTRAL ARTERIOVENOUS ANASTOMOSIS ARE MEDIATED THROUGH PROFOUND REDUCTION IN SYSTEMIC VASCULAR RESISTANCE. nameOfConference


  • Ridker PM, Everett BM, Thuren T et al. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. nameOfConference


    QMRO: qmroHref
  • Ridker PM, Revkin J, Amarenco P et al. (2017). Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. nameOfConference


    QMRO: qmroHref
  • Wolff CB, Nickol AH, Collier DJ (publicationYear). Arterial Oxygen Saturation During Ascent to 5010 m: Heart Rate and AMS Scores. nameOfConference


    QMRO: qmroHref
  • Saxena M, Shour T, Shah M et al. (2017). Attenuation of splanchnic autotransfusion following non-invasive ultrasound renal denervation: a novel marker of procedural success. nameOfConference

    DOI: doi

  • Floyd CN, Adeel MY, Wolff CB et al. (2016). First-in-man treatment of severe blood pressure variability with baroreflex activation therapy. nameOfConference


  • Lobo MD, Adeel MY, Wolff CB et al. (2016). [OP.8D.02] FIRST IN MAN TREATMENT OF SEVERE BP VARIABILITY WITH BAROREFLEX ACTIVATION THERAPY.. nameOfConference


  • Wolff C, Julu PO, Collier DJ et al. (2016). [PP.38.09] EFFECTS OF MILD DYNAMIC EXERCISE ON CIRCULATORY AND AUTONOMIC FUNCTION IN HEALTHY VOLUNTEERS. nameOfConference


  • Saxena M, Sobotka PA, Hamshere SM et al. (2016). Antihypertensive effects of a central arteriovenous anastomosis are mediated through profound reduction in systemic vascular resistance. nameOfConference


  • Collier DJ, Wolff CB, Hedges A-M et al. (2016). Benzolamide improves oxygenation and reduces acute mountain sickness during a high-altitude trek and has fewer side effects than acetazolamide at sea level. nameOfConference


  • Burchell AE, Chan K, Ratcliffe LEK et al. (2016). Controversies Surrounding Renal Denervation: Lessons Learned From Real‐World Experience in Two United Kingdom Centers. nameOfConference


    QMRO: qmroHref
  • Madurasinghe VW, Sandra Eldridge on behalf of MRC START Group and Gordon Forbes on behalf of the START Expert Consens (2016). Guidelines for reporting embedded recruitment trials. nameOfConference


  • Wolff CB, Collier DJ, Shah M et al. (2016). A Discussion on the Regulation of Blood Flow and Pressure. nameOfConference


    QMRO: qmroHref
  • Bower P, Rick J, Kennedy A et al. (2015). Testing the effectiveness of user-tested patient information on recruitment rates across multiple trials: meta-analysis of data from the start programme. nameOfConference


    QMRO: qmroHref
  • Eftychiou S, Shah M, Collier D et al. (2015). Independent responses of baroreceptors and blood pressure to low bolus dose of phenylephrine in fully conscious human volunteers. nameOfConference


    QMRO: qmroHref
  • Man M-S, on behalf of the Healthlines Study Group, Rick J et al. (2015). Improving recruitment to a study of telehealth management for long-term conditions in primary care: two embedded, randomised controlled trials of optimised patient information materials. nameOfConference


  • Saxena M, Collier D, Jain A et al. (2015). 8C.09. nameOfConference


    QMRO: qmroHref
  • Juhasz A, Collier D, Caulfield M et al. (2015). Achievement of Blood Pressure Targets and Safety of Azilsartan Medoxomil/Chlorthalidone Fixed Dose Combination versus Azilsartan Medoxomil in Hypertensive Patients Uncontrolled on Monotherapy. nameOfConference


    QMRO: qmroHref
  • Khanji M, Balawon A, Boubertakh R et al. (2015). LB01.07. nameOfConference


  • Rull G, Mohd-Zain Z, Shiel J et al. (2015). Effects of High Flavanol Dark Chocolate on Cardiovascular Function and Platelet Aggregation.. nameOfConference


  • Saxena M, Collier D, Jain A et al. (2015). A central iliac arteriovenous anastomosis results in durable and substantial blood pressure reduction in a woman with uncontrolled hypertension and multiple antihypertensive drug intolerances. nameOfConference

    DOI: doi

  • Burchell AE, Chan K, Hart EC et al. (2015). Challenges facing renal denervation: insight from real world experience at two UK centres. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Lobo MD, de Belder MA, Cleveland T et al. (2015). Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. nameOfConference


  • Rick J, Graffy J, Knapp P et al. (2014). Systematic techniques for assisting recruitment to trials (START): Study protocol for embedded, randomized controlled trials. nameOfConference


    QMRO: qmroHref
  • Rick J, Graffy J, Knapp P et al. (2014). Systematic techniques for assisting recruitment to trials (START): study protocol for embedded, randomized controlled trials. nameOfConference


  • Davies JE, Lacy P, Tillin T et al. (2014). Excess pressure integral predicts cardiovascular events independent of other risk factors in the conduit artery functional evaluation substudy of Anglo-Scandinavian Cardiac Outcomes Trial.. nameOfConference


    QMRO: qmroHref
  • Saxena M, Jain A, Mathur A et al. (2014). Early reduction in blood pressure and heart rate variability following multielectrode radio-frequency renal denervation in medicines intolerant patients. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Burchell A, Chan K, Ratcliffe L et al. (2014). Highly variable response to renal denervation for resistant hypertension - real world experience from 2 UK centres. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Hall DP, MacCormick IJC, Phythian-Adams AT et al. (2014). Network analysis reveals distinct clinical syndromes underlying acute mountain sickness.. nameOfConference


  • Bower P, Collier D, Eldridge S et al. (2013). A multimedia intervention to enhance recruitment to clinical trials in primary care and community settings: process of development and evaluation. nameOfConference


    QMRO: qmroHref
  • Rick J, Bower P, Collier D et al. (2013). Systematic techniques for assisting recruitment to trials (START): developing the science of recruitment. nameOfConference


    QMRO: qmroHref
  • Elkhawad M, Rudd JHF, Sarov-Blat L et al. (2012). Effects of p38 Mitogen-Activated Protein Kinase Inhibition on Vascular and Systemic Inflammation in Patients With Atherosclerosis. nameOfConference


    QMRO: qmroHref
  • Wolff CB, Bell M, Thake CD et al. (2012). Oscillations in cardiac output in hypoxia with periodic breathing and constant end-tidal PCO₂ at high altitude (5,000 m).. nameOfConference


    QMRO: qmroHref
  • Saxena M, Collier D, Caulfield M et al. (2012). Patients with resistant hypertension warrant a trial of salt restriction before and after renal denervation (RD). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Chan K, Ng FL, Saxena M et al. (2012). Renal denervation in resistant hypertension-a prospective case series. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Collier DJ, Poulter NR, Dahlöf B et al. (2011). Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Poulter NR, Dahlöf B et al. (2011). Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.. nameOfConference


    QMRO: qmroHref
  • Cheriyan J, Webb AJ, Sarov-Blat L et al. (2011). Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide-Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia. nameOfConference


    QMRO: qmroHref
  • Cascade E, Collier D, Kula-Przezwanski C (2011). IMPROVING PATIENT SAFETY IN THE UK AND ENGAGING PATIENTS IN RESEARCH: A NEW MODEL FOR THE NHS?. nameOfConference


    QMRO: qmroHref
  • Gupta A, Chang CL, Collier D et al. (2011). THE RELATIONSHIP BETWEEN STATIN THERAPY AND PROGRESSION OF RENAL DAMAGE AMONG 10305 HYPERTENSIVE PATIENTS RANDOMISED IN THE ASCOT-LIPID-LOWERING ARM (LLA). nameOfConference


    QMRO: qmroHref
  • Chik Z, Tucker AT, Shiel JI et al. (2010). Comparative Pharmacokinetic Assessments of Topical Drugs: Evaluation by Dermatopharmacokinetics, Microdialysis, and Systemic Measurement. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Robson J, Scott R et al. (2010). HiLo: a health services intervention study: methods and interim results on the first 2000 patients at 1 year. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Gupta AK, Poulter NR, Dobson J et al. (2010). Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial. nameOfConference


    QMRO: qmroHref
  • Davies JE, Lacy PS, Cruickshank K et al. (2010). Excess pressure is higher in atenolol-treated individuals and independently predicts cardiovascular events in the CAFE substudy of ASCOT. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Dolan E, Caulfield M, Thom S et al. (2010). AMBULATORY ARTERIAL STIFFNESS INDEX PREDICTS CARDIOVASCULAR MORBIDITY AND MORTALITY IN TREATED HYPERTENSIVE PATIENTS - AN ANGLO - SCANDINAVIAN CARDIAC OUTCOME TRIAL SUB-STUDY. nameOfConference


    QMRO: qmroHref
  • Davies J, Tillin T, Malaweera A et al. (2010). EXCESS PRESSURE IS HIGHER IN ATENOLOL-TREATED INDIVIDUALS AND INDEPENDENTLY PREDICTS CARDIOVASCULAR EVENTS IN THE CAFE SUBSTUDY OF ASCOT: HT.2.03. nameOfConference


    QMRO: qmroHref
  • Graffy J, Bower P, Ward E et al. (2010). Trials within trials? Researcher, funder and ethical perspectives on the practicality and acceptability of nesting trials of recruitment methods in existing primary care trials. nameOfConference


  • Elkhawad M, Rudd JH, Sarov-Blat L et al. (2010). Inhibition of p38 Mitogen-Activated Protein Kinase Attenuates Vascular and Systemic Inflammation in Patients with Atherosclerosis as Assessed by 18-F Fluorodeoxyglucose PET-CT. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Davies JE, Malaweera A, Lacy PS et al. (2010). P9.03 Wave Pressure is Higher in Atenolol-Treated Individuals and Independently Predicts Cardiovascular Events in the Cafe Substudy of Ascot. nameOfConference


    QMRO: qmroHref
  • Davies JE, Tillin T, Malaweera A et al. (2010). Pressure-Independent Pulsatility Index (PIPI) Independently Predicts Cardiovascular Events in the Cafe Sub-Study of Ascot. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Dolan E, Stanton AV, Thom S et al. (2009). Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - an Anglo-Scandinavian cardiac outcomes trial substudy. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Stride TJ, He S et al. (2009). Impact of Lifestyle Changes During Five Years of Drug Treatment in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Williams B, Lacy PS, Cruickshank JK et al. (2009). Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics Principal Results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study. nameOfConference


    QMRO: qmroHref
  • Hawa MI, Thivolet C, Mauricio D et al. (2009). Metabolic Syndrome and Autoimmune Diabetes: Action LADA 3. nameOfConference


  • Hawa MI, Cipponeri E, Collier D et al. (2008). The prevalence of metabolic syndrome is much less in LADA and type 1 diabetes than type 2 diabetes: ACTION LADA 3. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Collier DJ, Nickol AH, Milledge JS et al. (2008). Alveolar PCO2 oscillations and ventilation at sea level and at high altitude.. nameOfConference


    QMRO: qmroHref
  • Mytton OT, Simpson A, Thompson AAR et al. (2008). Manual assessment of the initial fall in blood pressure after orthostatic challenge at high altitude.. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Davies LC, Bernardi L et al. (2007). Baroreceptor function changes with differing blood pressure treatment during the anglo-scandinavian cardiac outcomes trial: principal results from the cardiac autonomic reflex assessment trial (CARAT). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Collier D, Davies L, Bernardi L et al. (2007). Baroreceptor function changes with differing blood pressure treatment during the Anglo-Scandinavian Cardiac Outcomes Trial: Principal results from the Cardiac Autonomic Reflex Assessment Trial (CARAT). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Chik Z, Tucker AT, Shiel JI et al. (2007). Comparative pharmacokinetic assessments of topically applied drugs: evaluation by dermatopharmacokinetic, microdialysis and systemic measurement. nameOfConference


    QMRO: qmroHref
  • Collier D, Arunachalam G, Johnston A et al. (2007). Continuing reduction of microalbuminuria and proteinuria during follow-up for the Anglo-Scandinavian Cardiac Outcomes Trial dominance of duration and blood pressure over other effects. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Wolff CB, Thake CD, Truesdell A et al. (2007). Oxygen delivery at sea level and altitude (after slow ascent to 5000 meters), at rest and in mild exercise.. nameOfConference


    QMRO: qmroHref
  • Nickol AH, Leverment J, Richards P et al. (2006). Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study.. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Caulfield MJ, Poulter NR et al. (2006). Did older or younger patients benefit more from amlodipine based vs atenolol based therapy in ASCOT-BPLA?. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Williams B, Lacy PS, Thurston H et al. (2006). Response to letters regarding article, "differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) Study". nameOfConference


    QMRO: qmroHref
  • Williams B, Lacy PS, Thom SM et al. (2006). Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes - Principal results of the Conduit Artery Function Evaluation (CAFE) study. nameOfConference


    QMRO: qmroHref
  • Poulter NR, Dahlof B, Sever PS et al. (2006). Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Dahlof B, Sever PS, Poulter NR et al. (2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. nameOfConference


    QMRO: qmroHref
  • Sever PS, Poulter NR, Dahlöf B et al. (2005). Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).. nameOfConference


    QMRO: qmroHref
  • Lindgren P, Buxton M, Kahan T et al. (2005). Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).. nameOfConference


    QMRO: qmroHref
  • Wolff CB, Checkley SK, Bhageerutty G et al. (2005). Circulation time in man from lung to periphery as an indirect index of cardiac output.. nameOfConference


    QMRO: qmroHref
  • COLLIER DJ, Caulfield M, Kristinsson A et al. (2005). Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac OutcomesTrial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Kaimal S, Collier DJ, Myers SL et al. (2004). Understanding and managing fetal alcohol syndrome.. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Wilson S, Johnston A, Robson J et al. (2003). Comparison of methods to identify individuals at increased risk of coronary disease from the general population.. nameOfConference


    QMRO: qmroHref
  • Silber E, Sonnenberg P, Collier DJ et al. (2003). Clinical features of headache at altitude: a prospective study.. nameOfConference


    QMRO: qmroHref
  • Sever PS, Dahlof B, Poulter NR et al. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. nameOfConference


    QMRO: qmroHref
  • Jorga A, Collier D, Priston B et al. (2003). Adults' reactions to inhaled denatonium benzoate (Bitrex (R)). nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Wilson S, Johnston A, Collier DJ et al. (2003). Feasibility of enrolling patients to hypertension outcome trials based on an assessment of their cardiovascular risk. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Wilson S, Johnston A, Robson J et al. (2003). Predicting coronary risk in the general population--is it necessary to measure high-density lipoprotein cholesterol?. nameOfConference


    QMRO: qmroHref
  • COLLIER DJ, Caulfield M, Kristinsson A et al. (2003). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.. nameOfConference


    QMRO: qmroHref
  • Bailey DM, Davies B, Castell LM et al. (2003). Symptoms of infection and acute mountain sickness; associated metabolic sequelae and problems in differential diagnosis.. nameOfConference


    QMRO: qmroHref
  • Wolff CB, Checkley SK, Bhageerutty G et al. (2002). Circulation time in man from lung to periphery - pulse and non-pulse oximetry. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Woods DR, Pollard AJ, Collier DJ et al. (2002). Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and arterial oxygen saturation at high altitude.. nameOfConference


    QMRO: qmroHref
  • Wilson S, Johnston A, Robson J et al. (2002). Should we measure high density lipoprotein cholesterol in people with hypertension?. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Wolff CB, Barry P, Collier DJ (2002). Cardiovascular and respiratory adjustments at altitude sustain cerebral oxygen delivery -- Severinghaus revisited.. nameOfConference


    QMRO: qmroHref
  • Wilson CM, Bakewell SE, Miller MR et al. (2002). Increased resting bronchial tone in normal subjects acclimatised to altitude.. nameOfConference


    QMRO: qmroHref
  • Wilson S, Johnston A, Robson J et al. (2002). OR-4: Who should have their cholesterol measured? A comparison of selective cholesterol screening methods. nameOfConference


    QMRO: qmroHref
  • Collier DJ, Martin TA, Angell-James JE et al. (2002). P-334: Gender differences in carotid sinus baroreceptor reflexes in healthy young normal subjects and in ASCOT patients with treated essential hypertension. nameOfConference


    QMRO: qmroHref
  • Woods DR, Pollard AJ, Collier DJ et al. (2001). Increased arterial oxygen saturation conferred by the I allele of the angiotensin I-converting enzyme gene at high altitude. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Collier DJ, Bernardi L, Angell-James JE et al. (2001). Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease.. nameOfConference


    QMRO: qmroHref
  • Kirby PL, Caulfield MC, Collier DJ et al. (2001). Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group.. nameOfConference


    QMRO: qmroHref
  • Wilson S, Collier D, Johnston A et al. (2001). Evaluation of cardiovascular risk equations using the ASCOT cohort.. nameOfConference


    QMRO: qmroHref
  • Mason NP, Barry PW, Pollard AJ et al. (2000). Serial changes in spirometry during an ascent to 5,300 m in the Nepalese Himalayas.. nameOfConference


    QMRO: qmroHref
  • Nickol A, Collier D (1999). Kangchenjunga 1998. nameOfConference


    QMRO: qmroHref
  • Caulfield M, Collier D, O'Byrne S (1998). The genetic basis of hypertension: progress and opportunities.. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Pollard AJ, Collier D, Mason NP et al. (1997). Changes in lung function on ascent to altitude. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Pollard AJ, Barry PW, Mason NP et al. (1997). Hypoxia, Hypocapnia and Spirometry at Altitude. nameOfConference


    QMRO: qmroHref
  • Pollard AJ, Mason NP, Barry PW et al. (1996). Effect of altitude on spirometric parameters and the performance of peak flow meters.. nameOfConference


    QMRO: qmroHref
  • Barry PW, Mason NP, Collier D (1995). Mount Everest study supports use of capillary samples. nameOfConference


    QMRO: qmroHref
  • Collier D, Angell-James J (1991). 9 On the location of the defect in the carotid sinus baroreceptor reflex arc in human essential hypertension. nameOfConference


    QMRO: qmroHref
  • Angell-James JE, Collier DJ (1991). Modification of Carotid Baroreflex by Trigeminal Stimulation in Hypertensive Man. nameOfConference


    QMRO: qmroHref
  • Angell-James JE, Besser GM, Bouloux P et al. (1990). Naloxone infusion and carotid sinus baroreceptor reflex in resting man. nameOfConference

    DOI: doi

    QMRO: qmroHref
  • Collier DJ, Beales IL (1989). Drinking among medical students: a questionnaire survey.. nameOfConference


    QMRO: qmroHref
  • Angell-James JE, Collier DJ, de Daly MB (1987). Effects of Trigeminal Receptor Stimulation on the Baroreceptor Reflex Control of Heart Rate in Normal Man. nameOfConference


    QMRO: qmroHref
Back to top